Bioengineering novel chimeric microrna-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 2, 2015, Pages 131-141

  Wang, Wei Peng ^a,d   Ho, Pui Yan ^a   Chen, Qiu Xia ^a   Addepalli, Balasubrahmanyam ^b   Limbach, Patrick A ^b   Li, Mei Mei ^a   Wu, Wen Juan ^a   Jilek, Joseph L ^a   Qiu, Jing Xin ^c   Zhang, Hong Jian ^d   Li, Tianhong ^a   Wun, Theodore ^a   White, Ralph DeVere ^a   Lam, Kit S ^a   Yu, Ai Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; INTERLEUKIN 6; MICRORNA 34A; PRODRUG; PROTEIN; RIBONUCLEASE; TRANSFER RNA; UREA; ANTINEOPLASTIC AGENT; MICRORNA; MIRN34 MICRORNA, HUMAN;

A549 CELL LINE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE FAST PROTEIN LIQUID CHROMATOGRAPHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOENGINEERING; BIOSYNTHESIS; BLOOD CHEMISTRY; CANCER GROWTH; CANCER THERAPY; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP SEQUENCING; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; GENE EXPRESSION; GENE TARGETING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA PURIFICATION; SEQUENCE ANALYSIS; TUMOR XENOGRAFT; UREA NITROGEN BLOOD LEVEL; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; ISOLATION AND PURIFICATION; NUDE MOUSE; PHYSIOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOENGINEERING; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941555844     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.225631     Document Type: Article

References (42)

1. Alexandrov A, Chernyakov I, Gu W, Hiley SL, Hughes TR, Grayhack EJ, and Phizicky EM (2006) Rapid tRNA decay can result from lack of nonessential modifications. Mol Cell 21:87-96.
2. Bader AG (2012) miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 3:120.
3. Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, and Yu AM (2014) N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis 35:2264-2272.
4. Bodeman CE, Dzierlenga AL, Tally CM, Mulligan RM, Lake AD, Cherrington NJ, and McKarns SC (2013) Differential regulation of hepatic organic cation transporter 1, organic anion-transporting polypeptide 1a4, bile-salt export pump, and multidrug resistance-associated protein 2 transporter expression in lymphocyte-deficient mice associates with interleukin-6 production. J Pharmacol Exp Ther 347:136-144.
5. Butash KA, Natarajan P, Young A, and Fox DK (2000) Reexamination of the effect of endotoxin on cell proliferation and transfection efficiency. Biotechniques 29: 610-614, 616, 618-619.
6. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. (2007) Trans-activation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26:745-752.
7. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, and Stärkel P (2010) Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer 9:256.
8. Chen QX, Wang WP, Zeng S, Urayama S, and Yu AM (2015) A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res 43:3857-3869.
9. Costantini S, Di Bernardo G, Cammarota M, Castello G, and Colonna G (2013) Gene expression signature of human HepG2 cell line. Gene 518:335-345.
10. Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, and Müller A (2012) Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 26:2421-2424.
11. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134.
12. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, and Harris CC (1993) p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14:987-992.
13. Huang L, Jin J, Deighan P, Kiner E, McReynolds L, and Lieberman J (2013) Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol 31:350-356.
14. Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, and Osawa Y (2013) Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos 41:1725-1731.
15. Kasinski AL and Slack FJ (2011) Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11:849-864.
16. Kasinski AL and Slack FJ (2012) miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72:5576-5587.
17. Kelnar K, Peltier HJ, Leatherbury N, Stoudemire J, and Bader AG (2014) Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem 86:1534-1542.
18. Krivos KL, Addepalli B, and Limbach PA (2011) Removal of 3'-phosphate group by bacterial alkaline phosphatase improves oligonucleotide sequence coverage of RNase digestion products analyzed by collision-induced dissociation mass spectrometry. Rapid Commun Mass Spectrom 25:3609-3616.
19. Lee YS, Shibata Y, Malhotra A, and Dutta A (2009) A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev 23:2639-2649.
20. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, et al. (1991) p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51:4090-4096.
21. Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle J, Zeng S, Huang M, and Yu AM (2015) Chimeric miR-1291 biosynthesized efficiently in E. coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos DOI:115.064493 [published ahead of print].
22. Li MM, Wang WP, Wu WJ, Huang M, and Yu AM (2014) Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos 42: 1791-1795.
23. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69:7569-7576.
24. Li Z, Ender C, Meister G, Moore PS, Chang Y, and John B (2012) Extensive terminal and asymmetric processing of small RNAs from rRNAs, snoRNAs, snRNAs, and tRNAs. Nucleic Acids Res 40:6787-6799.
25. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17:211-215.
26. Ma L, Teruya-Feldstein J, and Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682-688.
27. Nelissen FH, Leunissen EH, van de Laar L, Tessari M, Heus HA, and Wijmenga SS (2012) Fast production of homogeneous recombinant RNA-towards large-scale production of RNA. Nucleic Acids Res 40:e102.
28. Nomoto K, Tsuta K, Takano T, Fukui T, Fukui T, Yokozawa K, Sakamoto H, Yoshida T, Maeshima AM, Shibata T, et al. (2006) Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126:608-615.
29. Novoa EM, Pavon-Eternod M, Pan T, and Ribas de Pouplana L (2012) A role for tRNA modifications in genome structure and codon usage. Cell 149:202-213.
30. Pan YZ, Zhou A, Hu Z, and Yu AM (2013) Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 41:1744-1751.
31. Ponchon L, Beauvais G, Nonin-Lecomte S, and Dardel F (2009) A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc 4:947-959.
32. Ponchon L and Dardel F (2007) Recombinant RNA technology: the tRNA scaffold. Nat Methods 4:571-576.
33. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, and Maitra A (2011) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10: 1470-1480.
34. Russell SP and Limbach PA (2013) Evaluating the reproducibility of quantifying modified nucleosides from ribonucleic acids by LC-UV-MS. J Chromatogr B Analyt Technol Biomed Life Sci 923-924:74-82.
35. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, and Zheng X (2008) Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582: 1564-1568.
36. Taucher M and Breuker K (2010) Top-down mass spectrometry for sequencing of larger (up to 61 nt) RNA by CAD and EDD. J Am Soc Mass Spectrom 21:918-929.
37. Wang Y, Shan X, Dai Y, Jiang L, Chen G, Zhang Y, Wang Z, Dong L, Wu J, Guo G, et al. (2015) Curcumin analog L48H37 prevents lipopolysaccaride-induced TLR4 signaling pathway activation and sepsis via targeting MD2. J Pharmacol Exp Ther 352:539-550.
38. Welch C, Chen Y, and Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017-5022.
39. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, and Bader AG (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70:5923-5930.
40. Yamakuchi M, Ferlito M, and Lowenstein CJ (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105:13421-13426.
41. Yao HW and Li J (2015) Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets. J Pharmacol Exp Ther 352:2-13.
42. Yu AM (2009) Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opin Drug Metab Toxicol 5:1513-1528.